The authors call for long-term studies to assess the impact of GLP-1 RAs on cardiovascular safety, bone health, growth, pubertal development, and other long-term outcomes, helping define their role in the long-term management of pediatric metabolic disease
Tuy nhin, mt s trng hp c th gp cc tc dng ph nh|: Bn nn gp bc s t vn s dng, chnh liu hay ngng thuc nu gp phi cc tc dng ph trn
Retrieved from Baystate Health
SGLT2 inhibitorrelated adverse effects, including genital mycotic infections, volume depletion, and rarely ketoacidosis, remain clinically relevant and should be considered when these agents are prescribed as part of combination therapy and importantly, the intrinsic risk of hypoglycemia with combined GLP-1 receptor agonist and SGLT2 inhibitor therapy is low because neither class directly stimulates insulin secretion in a glucose-independent manner and when hypoglycemia occurs, it is more commonly related to concomitant insulin or sulfonylurea use rather than the combination itself [41, 42, 44]
It has also been shown to have superior bioavailability, which means it is easily absorbed and utilised by the body
UDCA, a hydrophilic bile salt, enhances the expression and nuclear translocation of Nrf2 thereby increasing expression of GSH synthesizing enzymes and the GSH level through PI3K/Akt pathway [87, 4]
